Zobrazeno 1 - 5
of 5
pro vyhledávání: '"James Fredric Strauss"'
Autor:
Mehmet Akce, Siwen Hu-Lieskovan, Matthew Reilley, James Fredric Strauss, Jennifer M. Specht, Mark N. Stein, Judy S. Wang, Jennifer Hsing Choe, Rom Leidner, Diwakar Davar, Gerald Steven Falchook, Shubham Pant, Ezra E.W. Cohen, Breelyn A. Wilky, Benjamin Thompson, Raphael Clynes, Lingling Li, Patricia McGovern, David Neal Liebowitz
Publikováno v:
Journal of Clinical Oncology. 40:2604-2604
2604 Background: XmAb23104 is a bispecific antibody targeting T cells that simultaneously express PD-1, an immune checkpoint, and ICOS, a costimulatory molecule expressed after T cell activation. DUET-3 is a Phase 1, first-in-human, dose-escalation a
Autor:
Wen Wee Ma, Anthony W. Tolcher, James Fredric Strauss, Tanios S. Bekaii-Saab, Yujie Zhao, Cesar Augusto Perez, Erika P. Hamilton, Gregory Paul Adams, Catherine Reddick, Eliel Bayever
Publikováno v:
Journal of Clinical Oncology. 40:TPS3158-TPS3158
TPS3158 Background: ELU001 is a novel, first-in-class, new molecular entity described as a C’Dot Drug Conjugate (CDC). ELU001 consists of ̃12 folic acid targeting moieties and ̃22 exatecan topoisomerase-1 inhibitor payloads on Cathepsin-B cleavab
Autor:
Chia-Chi Lin, Jaspreet Singh Grewal, David Sommerhalder, James Fredric Strauss, Li-Yuan Bai, Lin Shen, Yu-Min Yeh, Chih-Yi Hsieh, Sui Xiong Cai, Ye Edward Tian, Huan Xia, Congcong Zhang, Baoyue Li, Ming Zhang, Ning Ma, Liping Zhao, Jie Ma, Huiyan Shi, Zhixin Yu
Publikováno v:
Journal of Clinical Oncology. 40:e15052-e15052
e15052 Background: WEE1 kinase is a cell-cycle regulator that is important in DNA repair, and a validated antitumor target. IMP7068 is a potent and selective WEE1 inhibitor that has demonstrated antitumor activity in preclinical pharmacological model
Autor:
Ulka N. Vaishampayan, Piotr Tomczak, Jameel Muzaffar, Ira Seth Winer, Seth David Rosen, Christopher J. Hoimes, Aman Chauhan, Anna Spreafico, Karl D. Lewis, Debora S. Bruno, Olivier Dumas, David F. McDermott, James Fredric Strauss, Quincy S. Chu, Lucy Gilbert, Arvind Chaudhry, Julie R. Graham, Valentina Boni, Marc S. Ernstoff, Vamsidhar Velcheti
Publikováno v:
Journal of Clinical Oncology. 40:2500-2500
2500 Background: Nemvaleukin alfa (nemvaleukin, ALKS 4230) is a novel, engineered cytokine that selectively binds to the intermediate-affinity interleukin-2 (IL-2) receptor (IL-2R) to preferentially activate antitumor CD8+ T cells and natural killer
Autor:
Sant P. Chawla, Kathleen Batty, Masa Aleckovic, Vivek Bhadri, Nam Bui, Alexander David Guminski, Jose Manuel Mejia Oneto, Sangeetha Srinivasan, James Fredric Strauss, Vivek Subbiah, Mia C. Weiss, Rosalind Wilson, Nathan A. Yee, Michael Zakharian, Vineet Kwatra
Publikováno v:
Journal of Clinical Oncology. 40:3085-3085
3085 Background: SQ3370, a novel therapy, utilizes Shasqi’s proprietary Click Activated Protodrugs Against Cancer (CAPAC) platform where mutually-reactive click chemistry groups release Doxorubicin (Dox) at the tumor site minimizing systemic exposu